Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News

Tag: atrial fibrillation


Glycemic control and atrial fibrillation: an intricate relationship, yet under investigation

March 14th 2022

This review evaluates current anti-hyperglycemic treatment in the context of AF, and discusses AF-related decision-making in comorbid DM (Cardiovascular Diabetology)

Categories: Cardiovascular, News
Tags: atrial fibrillation, glycaemic control

Categories: Cardiovascular
Tags: atrial fibrillation, glycaemic control

SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system

February 12th 2021

In a large pharmacovigilance database, AF was robustly and consistently reported more frequently for diabetes medications other than SGLT2i. This finding complements available evidence from trials supporting a protective role of SGLT2i against the occurrence of AF (Cardiovascular Diabetology)

Categories: Cardiovascular, News
Tags: atrial fibrillation, SGLT2 inhibitors

Categories: Cardiovascular
Tags: atrial fibrillation, SGLT2 inhibitors

Prognostic significance of diabetes mellitus in patients with atrial fibrillation

February 12th 2021

The presence of DM on top of AF was associated with substantially increased risk for all-cause or CV mortality, sudden cardiac death and excess morbidity (Cardiovascular Diabetology)

Categories: Cardiovascular, News
Tags: atrial fibrillation

Categories: Cardiovascular
Tags: atrial fibrillation

Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes?

January 7th 2020

sodium-glucose co-transporter 2 inhibitors (SGLT2i) empagliflozin has the capacity to restore mitochondrial function, ameliorate electrical and structural remodelling and prevent AF (Cardiovascular Diabetology)

Categories: Cardiovascular, News
Tags: atrial fibrillation

Categories: Cardiovascular
Tags: atrial fibrillation

Role of diabetes and insulin use in the risk of stroke and acute myocardial infarction in patients with atrial fibrillation

May 13th 2019

There is an incremental risk of ischemic stroke and MI from non-diabetics to non-insulin diabetics with the highest risk in insulin users. Protective effect of anticoagulation is attenuated with insulin use (American Heart Journal)

Categories: Cardiovascular, News
Tags: anticoagulation, atrial fibrillation, insulin

Categories: Cardiovascular
Tags: anticoagulation, atrial fibrillation, insulin

Effect of Diabetes and Glycemic Control on Ischemic Stroke Risk in AF Patients

January 19th 2016

Duration of diabetes is a more important predictor of ischemic stroke than glycemic control in patients who have diabetes and AF (JACC)

Categories: Cardiovascular, News
Tags: atrial fibrillation

Categories: Cardiovascular
Tags: atrial fibrillation

Risk of atrial fibrillation in diabetes mellitus: A nationwide cohort study

August 10th 2015

Diabetes is an independent risk factor for developing atrial fibrillation/flutter, most pronounced in young diabetes patients. Routine screening for atrial fibrillation/flutter in diabetes patients might be beneficial and have therapeutic implications, especially in younger diabetes patients (Preventative Cardiology)

Categories: Cardiovascular, News
Tags: atrial fibrillation

Categories: Cardiovascular
Tags: atrial fibrillation

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Gold Sponsors

AstraZenecaNovo NordiskNapp DiabetesBoehringer Ingelheim

Silver Sponsors

About Ascensia Diabetes CareAbbott Diabetes CareWelsh Endocrinology and Diabetes Society (WEDS)

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin CGM CKD closed-loop COVID-19 dapagliflozin DPP4 DPP4 inhibitors Empagliflozin exenatide GLP-1 RA GLP-1RA GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis liraglutide metformin microvascular mortality NAFLD NICE pioglitazone retinopathy semaglutide SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2022 Glycosmedia Partnership